RU2007117752A - Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера - Google Patents

Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера Download PDF

Info

Publication number
RU2007117752A
RU2007117752A RU2007117752/13A RU2007117752A RU2007117752A RU 2007117752 A RU2007117752 A RU 2007117752A RU 2007117752/13 A RU2007117752/13 A RU 2007117752/13A RU 2007117752 A RU2007117752 A RU 2007117752A RU 2007117752 A RU2007117752 A RU 2007117752A
Authority
RU
Russia
Prior art keywords
amino acid
seq
polypeptide according
polypeptide
beta
Prior art date
Application number
RU2007117752/13A
Other languages
English (en)
Russian (ru)
Inventor
Марк ЛОВЕРЕЙС (BE)
Марк ЛОВЕРЕЙС
ЛЕУВЕН Фред ВАН (BE)
ЛЕУВЕН Фред ВАН
ДЕР АУВЕРА Ингрид ВАН (BE)
Дер Аувера Ингрид Ван
Стефан ВЕРА (BE)
Стефан Вера
Паскаль МЕРШЬЕ (BE)
Паскаль Мершье
Original Assignee
Аблинкс Н.В. (Be)
Аблинкс Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аблинкс Н.В. (Be), Аблинкс Н.В. filed Critical Аблинкс Н.В. (Be)
Publication of RU2007117752A publication Critical patent/RU2007117752A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2007117752/13A 2004-10-13 2005-10-13 Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера RU2007117752A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61814804P 2004-10-13 2004-10-13
US60/618,148 2004-10-13
US71861705P 2005-09-20 2005-09-20
US60/718,617 2005-09-20

Publications (1)

Publication Number Publication Date
RU2007117752A true RU2007117752A (ru) 2008-11-20

Family

ID=36148693

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007117752/13A RU2007117752A (ru) 2004-10-13 2005-10-13 Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера

Country Status (10)

Country Link
US (1) US20080107601A1 (enExample)
EP (1) EP1814917A2 (enExample)
JP (1) JP5113523B2 (enExample)
KR (1) KR20070084170A (enExample)
AU (1) AU2005293752A1 (enExample)
BR (1) BRPI0518151A2 (enExample)
CA (1) CA2583017A1 (enExample)
IL (1) IL182116A0 (enExample)
RU (1) RU2007117752A (enExample)
WO (1) WO2006040153A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2518291C2 (ru) * 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения

Families Citing this family (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
ES2694247T3 (es) * 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
EP1785434A1 (en) * 2005-11-11 2007-05-16 Ludwig-Maximilians-Universität München Targeting and tracing of antigens in living cells
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
ES2454253T3 (es) 2005-12-12 2014-04-10 Ac Immune S.A. Anticuerpos monoclonales específicos de beta A 1-42 con propiedades terapéuticas
US20100226920A1 (en) * 2006-03-27 2010-09-09 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
KR101605207B1 (ko) 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
CA2663042A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20100034194A1 (en) * 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
JP2010505435A (ja) * 2006-10-11 2010-02-25 アブリンクス エン．ヴェー． 本質的にｐＨに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用
JP2010507624A (ja) * 2006-10-27 2010-03-11 アブリンクス エン．ヴェー． ポリペプチド及びタンパク質の鼻内送達
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2101801A1 (en) * 2006-12-20 2009-09-23 Ablynx N.V. Oral delivery of polypeptides
US7939075B2 (en) 2007-01-11 2011-05-10 Philipps-Universitaet Marburg Human monoclonal anti-amyloid-beta antibodies
KR101160385B1 (ko) * 2007-01-18 2012-07-10 일라이 릴리 앤드 캄파니 페길화된 Ａβ ＦＡＢ
US20110118185A9 (en) * 2007-02-21 2011-05-19 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP3202786A3 (en) 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
EP1978035A1 (en) * 2007-04-05 2008-10-08 Hans-Knöll-Institut Leibniz-Institut für Naturstoff-Forschung Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
MX2009011523A (es) 2007-04-27 2009-11-09 Dow Global Technologies Inc Metodo para clasificar rapidamente huespedes microbianos para identificar ciertas cepas con rendimiento y/o calidad mejorados en la expresion de proteinas heterologas.
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PL2170389T3 (pl) * 2007-06-12 2015-03-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
EP2008666A1 (en) 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
EP2009445A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications
WO2009004065A2 (en) 2007-07-03 2009-01-08 Ablynx N.V. Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
AU2008276787B2 (en) 2007-07-13 2013-06-06 Bac Ip B.V. Single-domain antigen-binding proteins that bind mammalian IgG
ES2445590T3 (es) * 2007-10-05 2014-03-04 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
RU2571859C2 (ru) * 2007-10-05 2015-12-20 Дженентек, Инк. Применение антитела против амилоида-бета при глазных заболеваниях
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2215125A1 (en) * 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
EP2068124A1 (en) 2007-12-04 2009-06-10 Metris IPR N.V. Articulated arm measuring machine endowed with multiple measurement disks
AU2009221106A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
EP2281005B1 (en) 2008-04-03 2013-11-20 Vib Vzw Single domain antibodies capable of modulating bace1 activity
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
AU2009273251B2 (en) 2008-07-22 2014-12-18 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
CA2736904A1 (en) 2008-09-26 2010-04-01 Wyeth Llc Compatible display vector systems
WO2010036860A2 (en) * 2008-09-26 2010-04-01 Wyeth Llc Compatible display vector systems
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
EP4104821A1 (en) 2008-10-29 2022-12-21 Ablynx N.V. Formulations of single domain antigen binding molecules
AU2009329501B2 (en) 2008-12-19 2015-11-26 Ablynx N.V. Genetic immunization for producing immunoglobulins against cell-associated antigens such as P2X7, CXCR7 or CXCR4
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
WO2010115998A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
PT2424889E (pt) 2009-04-30 2015-11-12 Ablynx Nv Método de produção de anticorpos de domínio
CA2761298A1 (en) * 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
US9968574B2 (en) * 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
NZ597314A (en) * 2009-06-05 2013-07-26 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
FI3725330T3 (fi) 2009-09-03 2025-11-14 Ablynx Nv Polypeptidien stabiilit valmisteet ja niiden käyttötarkoitukset
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CN102753148B (zh) 2010-02-11 2018-01-26 埃博灵克斯股份有限公司 用于制备气雾剂的方法和组合物
WO2011098518A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
EA201201227A1 (ru) * 2010-03-03 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Бипаратопные а-бета-связывающие полипептиды
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
EP2593476A2 (en) * 2010-07-16 2013-05-22 Ablynx N.V. Modified single domain antigen binding molecules and uses thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
PL2632946T3 (pl) 2010-10-29 2018-06-29 Ablynx N.V. Sposób wytwarzania pojedynczych domen zmiennych immunoglobulin
ES2723775T3 (es) 2010-11-08 2019-09-02 Ablynx Nv Polipéptidos que se unen a CXCR2
DK2643349T3 (da) 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
PT2691415T (pt) 2011-03-28 2018-10-19 Ablynx Nv Método para produção de formulações sólidas compreendendo domínios variáveis únicos de imunoglobulina
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9534039B2 (en) 2011-05-09 2017-01-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
BR112013030298A2 (pt) 2011-05-27 2017-12-12 Ablynx Nv inibição da reabsorção óssea com peptídeos que se ligam ao rankl
IN2014CN00437A (enExample) 2011-06-23 2015-04-03 Ablynx Nv
EP2753644A1 (en) 2011-09-09 2014-07-16 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
CA2849195A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
US10112988B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
IL311502A (en) 2012-02-27 2024-05-01 Ablynx Nv Cx3cr1-binding polypeptides
USRE49625E1 (en) 2012-03-29 2023-08-29 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Nanoscale process to generate reagents selective for individual protein variants
US9938330B2 (en) 2012-03-29 2018-04-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Nanoscale process to generate reagents selective for individual protein variants
NZ628584A (en) 2012-03-30 2016-04-29 Boehringer Ingelheim Int Ang2-binding molecules
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
JP6411333B2 (ja) 2012-05-24 2018-10-24 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 腫瘍関連マクロファージのターゲティングおよびｉｎｖｉｖｏイメージング用抗マクロファージマンノース受容体単一可変ドメイン
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
EP2931749B1 (fr) 2012-12-17 2019-04-24 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
US20150368339A1 (en) 2013-02-05 2015-12-24 Vib Vzw Muscarinic acetylcholine receptor binding agents and uses thereof
NO2951201T3 (enExample) 2013-02-08 2018-03-17
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
KR20160003634A (ko) 2013-02-13 2016-01-11 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-her2 항체 및 이의 용도
EP2956484B1 (en) 2013-02-13 2018-11-14 Laboratoire Français du Fractionnement et des Biotechnologies Cetuximab with modified glycosylation and uses thereof
CN105051067B (zh) 2013-03-12 2020-04-17 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
JP6457999B2 (ja) 2013-03-14 2019-01-23 ザ チルドレンズ メディカル センター コーポレーション 処置に関してがんの対象を識別するためのｃｄ３６の使用
WO2014140376A1 (en) 2013-03-15 2014-09-18 Vib Vzw Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
JP6415827B2 (ja) * 2013-09-08 2018-10-31 株式会社テクノメデイカ 紙装置を用いたトランスフェリンファミリータンパク質の検出
PT3060908T (pt) 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
EP2873679A1 (en) * 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof
EP2873680A1 (en) * 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
EP2899208A1 (en) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
EP3134730A4 (en) 2014-04-24 2018-01-17 Immusant Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines
SI3248986T1 (sl) 2014-05-16 2022-04-29 Ablynx Nv Variabilne domene imunoglobulina
EP4043011A1 (en) 2014-05-16 2022-08-17 Children's Hospital Medical Center Methods for assessing responsiveness to asthma treatment based on vnn-1 expression and promoter methylation
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
EP3207048A4 (en) 2014-10-17 2018-05-30 The Broad Institute, Inc. Compositions and methods of treating muscular dystrophy
EP3230457B1 (en) 2014-12-09 2021-06-30 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
PT3233910T (pt) 2014-12-19 2020-03-17 Ablynx Nv Dímeros de nanocorpos ligados a cisteína
SG11201705986QA (en) 2015-01-29 2017-08-30 Technophage Investigação E Desenvolvimento Em Biotecnologia Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
CN107646039B (zh) 2015-04-02 2022-04-15 埃博灵克斯股份有限公司 具有有效抗hiv活性的双特异性cxcr4-cd4多肽
LT3611192T (lt) 2015-05-13 2025-06-25 Ablynx N.V. T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
DK3294319T3 (da) 2015-05-13 2024-07-22 Ablynx Nv T-celle-rekrutterende polypeptider baseret på cd3-reaktivitet
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US10973912B2 (en) 2015-06-29 2021-04-13 President And Fellows Of Harvard College Treatment for myopathy
EP3350595B1 (en) 2015-09-14 2021-08-04 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
NO2768984T3 (enExample) 2015-11-12 2018-06-09
CA3003777A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
MA43260A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
CA3004900C (en) 2015-11-18 2021-08-10 Merck Sharp & Dohme Corp. Ctla4 binders
KR20180080337A (ko) 2015-11-27 2018-07-11 아블린쓰 엔.브이. Ｃｄ40ｌ을 억제하는 폴리펩티드
UA122079C2 (uk) 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
US20190127447A1 (en) 2016-05-02 2019-05-02 Ablynx N.V. Treatment of rsv infection
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
EP3541846A1 (en) 2016-11-16 2019-09-25 Ablynx NV T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
BR112019012667A2 (pt) 2016-12-23 2020-02-11 Novartis Ag Anticorpos do fator xi e métodos de uso
KR102616335B1 (ko) 2017-02-28 2023-12-21 브이아이비 브이지더블유 경구 단백질 전달을 위한 수단 및 방법
JP6877722B2 (ja) * 2017-03-31 2021-05-26 国立大学法人 東京大学 ノロウイルス抗体
JP7678244B2 (ja) 2017-05-11 2025-05-16 ブイアイビー ブイゼットダブリュ 可変免疫グロブリンドメインのグリコシル化
MA48760A (fr) 2017-05-31 2020-04-08 Boehringer Ingelheim Int Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales
KR102740376B1 (ko) 2017-06-02 2024-12-09 메르크 파텐트 게엠베하 Adamts5, mmp13 및 아그레칸 결합성 폴리펩타이드
US11261260B2 (en) 2017-06-02 2022-03-01 Merck Patent Gmbh ADAMTS binding immunoglobulins
US12129308B2 (en) 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins
MX2019014504A (es) 2017-06-02 2020-07-20 Merck Patent Gmbh Inmunoglobulinas de union a agrecano.
WO2018220169A1 (en) 2017-06-02 2018-12-06 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy
CN111108126B (zh) 2017-07-19 2024-04-26 非营利性组织佛兰芒综合大学生物技术研究所 血清白蛋白结合剂
KR20200091400A (ko) 2017-10-31 2020-07-30 브이아이비 브이지더블유 신규한 항원-결합 키메라 단백질 및 이의 방법 및 용도
US12037382B2 (en) 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
AU2019217584B2 (en) 2018-02-06 2025-08-14 Ablynx Nv Methods of treating initial episode of TTP with immunoglobulin single variable domains
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
EP3758742A1 (en) 2018-03-01 2021-01-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
WO2020185069A1 (en) 2019-03-08 2020-09-17 Linxis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
AU2020250810A1 (en) 2019-03-29 2021-09-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN113646048A (zh) 2019-03-29 2021-11-12 勃林格殷格翰国际有限公司 抗癌组合疗法
CN114173809A (zh) 2019-04-02 2022-03-11 伊缪纯有限公司 免疫刺激组合物及其用途
KR20220016077A (ko) 2019-04-29 2022-02-08 콘포 테라퓨틱스 엔.브이. Gpcr에 결합하는 화합물 및 리간드를 스크리닝하는 키메라 단백질 및 방법
WO2020221888A1 (en) 2019-04-30 2020-11-05 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
EP3976067A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
US20220220197A1 (en) 2019-05-28 2022-07-14 Vib Vzw Cancer Treatment by Targeting Plexins in the Immune Compartment
US20220324947A1 (en) 2019-08-05 2022-10-13 Stichting Vu Identification and Elimination of HCMV-Infected Cells
CN111748571B (zh) * 2019-10-11 2022-05-03 浙江禾霖生物科技有限公司 一种将枯草芽孢杆菌工程化为生产纳米抗体的多功能稳定平台的方法
US20220380456A1 (en) 2019-10-21 2022-12-01 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
CA3160506A1 (en) 2019-11-11 2021-05-20 Ibi-Ag Innovative Bio Insecticides Ltd. Insect control nanobodies and uses thereof
EP4065603A1 (en) 2019-11-27 2022-10-05 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
US20240027467A1 (en) 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
IL295892A (en) 2020-02-25 2022-10-01 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
EP4144758A4 (en) 2020-04-22 2024-05-15 Mabwell (Shanghai) Bioscience Co., Ltd. SINGLE VARIABLE DOMAIN ANTIBODIES TARGETING AND DERIVED FROM HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1)
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
JP2023541934A (ja) 2020-09-16 2023-10-04 リンクシス ベスローテン フェンノートシャップ 内在化結合分子
CA3196737A1 (en) 2020-09-24 2022-03-31 Massimiliano Mazzone Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
MX2023003522A (es) 2020-09-25 2023-04-19 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
WO2022072255A1 (en) * 2020-09-30 2022-04-07 Merck Sharp & Dohme Corp. Binding proteins and antigen binding fragments thereof that bind abeta
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CA3206124A1 (en) 2020-12-24 2022-06-30 Vib Vzw Non-blocking human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders
EP4267621A1 (en) 2020-12-24 2023-11-01 Vib Vzw Murine cross-reactive human ccr8 binders
CN113150140B (zh) * 2021-01-25 2022-11-04 山西农业大学 一种sox6二价纳米抗体及其应用
AU2022216460A1 (en) 2021-02-05 2023-09-21 Universiteit Gent Sarbecovirus binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
CN117241804A (zh) 2021-02-17 2023-12-15 非营利性组织佛兰芒综合大学生物技术研究所 在癌症治疗中slc4a4的抑制
CA3211270A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
US20240369570A1 (en) 2021-04-09 2024-11-07 Stichting Radboud Universiteit Off the shelf proximity biotinylation enzyme
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
EP4355778A1 (en) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Novel tri-specific binding molecules
EP4359421A1 (en) 2021-06-23 2024-05-01 Vib Vzw Means and methods for selection of specific binders
WO2023274183A1 (zh) 2021-06-29 2023-01-05 江苏先声药业有限公司 Cd16抗体及其应用
WO2023004293A1 (en) 2021-07-20 2023-01-26 Lanzatech, Inc. Recombinant microorganisms and uses therefor
CA3228014A1 (en) 2021-07-30 2023-02-16 Vib Vzm Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
AU2022320667A1 (en) 2021-07-30 2024-03-14 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-pvrig/anti-tigit bispecific antibody and application
US20240271186A1 (en) 2021-08-03 2024-08-15 Wageningen Universiteit Argonaute-based nucleic acid detection system
CN118339180A (zh) * 2021-12-01 2024-07-12 爱普思隆分子进化工程株式会社 具有随机区搭载用框架序列的肽以及由该肽构成的肽文库
WO2023098846A1 (zh) 2021-12-03 2023-06-08 江苏先声药业有限公司 抗bcma纳米抗体及其应用
MX2024007564A (es) 2021-12-17 2024-07-04 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tcr\03b1\03b2, cd33 y cd123.
CN118510805A (zh) 2021-12-31 2024-08-16 山东先声生物制药有限公司 一种gprc5d抗体及其应用
CA3248241A1 (en) 2022-01-12 2023-07-20 Vib Vzw HUMAN NTCP BINDERS FOR THERAPEUTIC USE AND TARGETED LIVER ADMINISTRATION
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
US20250313611A1 (en) 2022-05-18 2025-10-09 Vib Vzw Sarbecovirus spike s2 subunit binders
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
IL317463A (en) 2022-06-06 2025-02-01 Shandong Simcere Biopharmaceutical Co Ltd Multispecific antibodies targeting BCMA, GPRC5D and T cells and their application
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
TWI850016B (zh) 2022-07-08 2024-07-21 丹麥商諾佛 儂迪克股份有限公司 能夠取代fviii(a)之高效isvd化合物
WO2024013402A1 (en) 2022-07-15 2024-01-18 Gadeta B.V. Novel soluble gamma t-cell (or soluble delta t-cell) receptor chains (or soluble gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024013315A1 (en) 2022-07-15 2024-01-18 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
MA71603A (fr) 2022-07-27 2025-05-30 Ablynx Nv Polypeptides se liant à un épitope spécifique du récepteur fc néonatal
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024084203A1 (en) * 2022-10-18 2024-04-25 Isogenica Limited Single domain antibodies binding to albumin
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
KR20250116642A (ko) 2022-10-28 2025-08-01 제노 바이오파마 컴퍼니 리미티드 새로운 항-ctla4 항체
EP4612180A1 (en) 2022-10-31 2025-09-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
EP4615493A1 (en) 2022-11-08 2025-09-17 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
JP2025537809A (ja) 2022-11-15 2025-11-20 アイメック・ヴェーゼットウェー 液滴操作のための方法およびシステム
AU2023394987A1 (en) 2022-12-15 2025-06-26 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
WO2024133301A1 (en) 2022-12-19 2024-06-27 Umc Utrecht Holding B.V. Btn2a1 binding peptide
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
AU2024208858A1 (en) 2023-01-20 2025-06-19 Boehringer Ingelheim International Gmbh Il-12 fc fusion proteins
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
EP4655323A1 (en) 2023-01-27 2025-12-03 Vrije Universiteit Brussel Cd8b-binding polypeptides
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
WO2024189171A1 (en) 2023-03-14 2024-09-19 Aarhus Universitet Genetically altered nfr5 receptor kinases
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
WO2024231348A1 (en) 2023-05-11 2024-11-14 Vib Vzw Slc4a4/nbce1 inhibitors
WO2024240162A1 (en) 2023-05-23 2024-11-28 Shanghai Allygen Biologics Co., Ltd. Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
WO2024251826A1 (en) 2023-06-05 2024-12-12 Vib Vzw Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2024251981A1 (en) 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024261344A1 (en) 2023-06-23 2024-12-26 Vib Vzw Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
GB202314424D0 (en) 2023-09-20 2023-11-01 Cambridge Entpr Ltd A conjugate
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025154058A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025154056A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect cda nanobodies and uses thereof
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025196308A1 (en) 2024-03-22 2025-09-25 Vib Vzw Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025210082A1 (en) * 2024-04-05 2025-10-09 UCB Biopharma SRL Heavy chain variable domains that bind to free light chains
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
GB202405566D0 (en) * 2024-04-19 2024-06-05 272Bio Ltd vnh antibodies
WO2025229159A1 (en) 2024-05-01 2025-11-06 Commit Biologics Aps Antibodies and antibody constructs against cd20

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
EP0279582A3 (en) * 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2110899C (en) * 1991-06-21 2006-08-08 Jacob G. Michael Orally administrable therapeutic proteins and method of making
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
DE69334095T2 (de) * 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
ATE452975T1 (de) * 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
WO1994017197A1 (fr) * 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
AU4964896A (en) * 1995-01-19 1996-08-07 Research Foundation Of The State University Of New York, The Genes encoding an insect calcium channel
EP0739981A1 (en) * 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) * 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
US6221645B1 (en) * 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
IL115465A0 (en) * 1995-09-29 1995-12-31 Yeda Res & Dev Assay for the diagnosis of dementia
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
CN1390232A (zh) * 1999-02-10 2003-01-08 艾兰制药公司 人β分泌酶、抑制剂、其组合物和用途
EP1328626B1 (en) * 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
FR2846667B1 (fr) * 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
EP1558646A2 (en) * 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
NZ540196A (en) * 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
CA2622968A1 (en) * 2005-09-23 2007-03-29 Academisch Ziekenhuis Leiden Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2518291C2 (ru) * 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения

Also Published As

Publication number Publication date
JP2008515446A (ja) 2008-05-15
US20080107601A1 (en) 2008-05-08
IL182116A0 (en) 2008-04-13
JP5113523B2 (ja) 2013-01-09
CA2583017A1 (en) 2006-04-20
WO2006040153A2 (en) 2006-04-20
BRPI0518151A2 (pt) 2009-06-16
AU2005293752A1 (en) 2006-04-20
KR20070084170A (ko) 2007-08-24
WO2006040153A3 (en) 2007-04-19
EP1814917A2 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
RU2007117752A (ru) Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера
JP7532571B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
JP2008515446A5 (enExample)
JP6936784B2 (ja) グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法
EP3402817B1 (en) Anti-n3-beta-glu amyloid beta peptide antibodies and uses thereof
US9573992B2 (en) Serum albumin binding proteins
EP3322715B1 (en) Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
EP1978035A1 (en) Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
RU2009147758A (ru) Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей
US20220281975A1 (en) Trem2 antibodies and uses thereof
US20160368979A1 (en) Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines
JP2019514994A (ja) 脊髄性筋萎縮症を治療するための組成物及び方法
EP3496750A2 (en) Combination therapy
TWI734279B (zh) 抗α-突觸核蛋白抗體及其用途
TW202340249A (zh) 生物活性降低之抗體變體
CN118206657B (zh) 一种半乳糖凝集素-3的抗体及其应用
CN116948024B (zh) 抗Tau蛋白的捕获抗体
EP4116420A1 (en) Use of gp73 inhibitor in preparation of medicine for treating diabetes
EP4558520A1 (en) Cx3cr1-binding compounds, uses thereof and related methods
US20250277027A1 (en) Antibody or antibody fragment that specifically binds to voltage-gated sodium channel alpha subunit nav1.7
EP4260872A1 (en) Agent for preventing or treating frontotemporal lobar degeneration
KR20250116724A (ko) 항-헌팅틴 항체
JP2008191135A (ja) 腎炎検出試薬
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20091016

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20091112

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100310